Krafton subsidiary seeks clinical trial approval for oral insulin drug SCD0503, targeting Type 1 diabetes patients and aiming for improved efficacy and convenience over injections.
The development of an oral insulin for Type 1 diabetes represents a significant advancement in diabetes treatment, potentially offering a more convenient and less invasive alternative to injections. Successful clinical trials and regulatory approval could lead to a substantial new revenue stream for Krafton's pharmaceutical arm and improve the quality of life for millions of diabetes patients globally.
Krafton subsidiary is pursuing clinical trial approval for SCD0503.
The drug is an oral insulin for Type 1 diabetes.
The trial will compare its efficacy and bioavailability to injected insulin.
This research and development activity is relevant to the global pharmaceutical and biotechnology markets, with potential implications for healthcare regulations and patient access in various regions.
The trial will compare its efficacy and bioavailability to injected insulin.
Krafton subsidiary is pursuing clinical trial approval for SCD0503.
Sign in to save notes on signals.
Sign In